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Abstract: Combivir is a ﬁ  xed dose combination tablet of two antiretroviral drugs; zidovudine 
and lamivudine, used in the treatment of HIV-1 infection. AZT was the ﬁ  rst antiretroviral used 
in clinical trials and the addition of lamivudine improved its effectiveness. With the introduction 
of highly active antiretroviral therapy in the form of a combination of three drugs including two 
nucleoside analogues, Combivir became the gold standard nucleoside ‘backbone’ until very 
recently. Combivir was the ﬁ  rst combination agent and simpliﬁ  ed HIV therapy greatly. The 
introduction of newer ﬁ  xed dose combinations with the advantage of once daily dosing and 
improved tolerability and toxicity proﬁ  les has made Combivir a less popular choice in treatment 
naïve individuals needing to start therapy.
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The ﬁ  rst ﬁ  xed dose combination antiretroviral
Combination antiretroviral therapy, sometimes called highly active combination 
therapy (HAART) has revolutionized the management of HIV infection and rendered 
it a chronic manageable disease (Palella 1998).
Most combination therapies for HIV use two nucleoside reverse transcriptase 
inhibitors (NRTI) as a backbone with a third agent either from the non-nucleoside 
reverse transcriptase inhibitor (NNRTI) class or a protease inhibitor to make up a 
very potent therapy that will successfully suppress viral replication and allow immune 
reconstitution (Dronda 2002).
Combivir™ (GlaxoSmithKline Ltd, Brentford Middlesex, UK) is a combina-
tion of two NRTI’s, azidothymidine (zidovudine, 3'-Azido-3'-deoxythymidine, 
AZT) which is a thymidine analogue, and lamivudine (2'-Deoxy-3'-thiacytidine, 
3TC, GlaxoSmithKline Ltd, Brentford Middlesex, UK ) a cytosine analogue. Each 
Combivir pill contains 300 mg of AZT and 150 mg of lamivudine and is taken every 
twelve hours with or without food. It was the ﬁ  rst ﬁ  xed dose combination therapy 
made available for HIV infected individuals. Combivir became available in 1997 and 
was licensed by the United States Food and Drug Administration (FDA) in October 
that year. The European launch followed in March 1998. Combivir has maintained a 
very important place in HIV management and here we discuss the history and utility 
of its two component agents. We describe the pivotal studies which for some time 
maintained Combivir as the preferred NRTI backbone. More recent developments in 
HIV therapy that have led to Combivir becoming a less chosen ﬁ  rst line option and 
we will discuss the future of Combivir in antiretroviral management.
AZT was developed in the 1960’s as an antitumor agent but was not used clini-
cally for this indication. When a cell line model for HIV infection became available, 
AZT was amongst the ﬁ  rst compounds screened by the then Wellcome pharmaceuti-
cal research laboratories (Personal communication GlaxoSmithKline UK Ltd). In 
1984 Wellcome started working on an assay that would be used to identify agents to Therapeutics and Clinical Risk Management 2007:3(4) 580
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inhibit HIV. AZT was one of the ﬁ  rst 100 compounds that 
ran through the assay and was found to have in vitro efﬁ  cacy 
at reducing reverse transcriptase activity (Furman 1986) and 
for attenuating the infectivity and cytopathic effects of this 
newly discovered virus (Mitsuya 1985). AZT was trialed 
as monotherapy in humans in the early 1980’s with notable 
improvements in clinical status noted (Yarchoan 1986). The 
076 study was a placebo controlled study that enrolled 287 
individual who were clinically classiﬁ  ed as having Acquired 
Immune Deﬁ  ciency Syndrome (AIDS) or AIDS related com-
plex. The results were dramatic and the study was unblinded 
and terminated early by the data safety monitoring commit-
tee. Only one death had occurred in the AZT arm compared 
to 19 deaths in the placebo arm and there was a signiﬁ  cant 
reduction in disease progression in those on active drug 
(Fischl 1987). AZT was found to have other beneﬁ  ts such 
as improvements in AIDS related neurological syndromes 
(Yarchoan 1987). These beneﬁ  ts however came at a cost with 
over 24% of those on AZT becoming profoundly anemic, and 
other toxicities such as myositis, macrocytosis, headaches 
and neutropenia recognised (Richman 1987). It must be noted 
that in this trial and in other earlier trials AZT was dosed at 
250 mg every four hours compared to the currently licensed 
dose of 250 mg twelve hourly or 300 mg twelve hourly as a 
component of Combivir. At these doses the drug is consider-
ably more tolerable and has less severe toxicity.
AZT was considered a potential therapy for HIV infec-
tion and a larger joint US and European study named ‘Con-
corde’ study was designed. Participants were enrolled in 
the Concorde study if they had not had a history of an AIDS 
diagnosis and were randomized to receive either 1000 mg 
a day of AZT (‘immediate treatment’) or placebo. Placebo 
recipients were switched to receive active drug on disease 
progression (‘delayed treatment’). Over 1700 participants 
were enrolled in the Concorde study with a view to compare 
the clinical outcomes of either disease progression or death in 
the two observed groups. After about one year into Concorde 
a further study of similar size and design, ACTG 019, had 
shown a slowing of CD4 decline but no clinical advantages 
in AZT use (Volberding 1990). The Concorde study ulti-
mately demonstrated that immediate or deferred AZT had 
no clinical advantage (Concorde Coordinating committee 
1994) and evidence was mounting that at the doses used 
had unwanted effects that may have had a negative overall 
effect on quality of life.
From what is now understood about HIV viral dynamics 
and the rapid emergence of resistant virus with incompletely 
suppressed virus, it is clear that monotherapy with an NRTI 
will have only short term beneﬁ  ts. AZT had been shown 
to have limited clinical effectiveness and it was clear that 
newer drugs were needed and then perhaps used in com-
bination together. Subsequently three new NRTI’s became 
available including the cytosine analogue lamivudine (3TC) 
(van Leeuwen 1992). In-vitro work suggested a combination 
of AZT with 3TC delayed the emergence of AZT resistant 
virus (Soudeyens 1991) and AZT resistant virus retained 
some susceptibility to 3TC. AZT continued to be used in 
monotherapy but further clinical trials of dual therapy with 
two NRTI’s including AZT showed a more dramatic slow-
ing of clinical disease progression (Staszewski 1996). It was 
also noted that 3TC was less cytotoxic than AZT and that 
with repeated passage of virus through culture there was a 
rapid emergence of viral resistance to 3TC with a mutation 
in the YMDD catalytic portion of reverse transcriptase with 
a substitution of valine for methionine at position 184 (Gao 
1993; Tisdale 1993). This mutation, known as the M184V, 
is the signature mutation for 3TC and is known to develop 
very rapidly with 3TC monotherapy or with virological fail-
ure of a 3TC containing combination (Pluda 1995). It was 
noted that 3TC was very well tolerated with headache and 
insomnia being the only major side effects. Serious toxicity 
was strikingly absent (Ingrand 1995). In clinical trials, dual 
therapy adding 3TC to AZT monotherapy resulted in sig-
niﬁ  cant virological suppression (Katlama 1996; Katzenstein 
2000) with the resulting clinical beneﬁ  ts of delayed disease 
progression (Staszewski 1997).
It was established that dual therapy was better than 
monotherapy, however the effects were short term and resis-
tance still developed albeit more slowly, leading to disease 
progression (Delta Coordinating committee 1996). In 1996 
trials of combination therapy with two NRTI’s and a protease 
inhibitor showed dramatic reductions in short term mortality in 
clinical trials (Steigbigel 1996). Subsequently another class of 
antiretroviral agents, the non-nucleoside reverse transcriptase 
inhibitors (NNRTI) were found to be effective in combina-
tion with two NRTI’s and thus the era of triple combination 
HAART was heralded. This triple combination therapy sup-
pressed circulating virus profoundly to levels below the limit 
of detection. With such limited viral replication a realistic goal 
of complete viral suppression and the prevention of resistant 
virus emerging was possible (Pollard 1999).
Other NRTI’s that became available had disadvantages 
over AZT and 3TC. The adenosine analogue, didanosine 
(ddI), was poorly absorbed and had to be chewed or dissolved 
and taken on an empty stomach with a bulky antacid buffer. 
Stavudine (d4T), another thymidine analogue was relative Therapeutics and Clinical Risk Management 2007:3(4) 581
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well tolerated but carried a high risk of the development of 
peripheral neuropathy. Zalcitabine (ddC) was poorly toler-
ated and caused unpleasant mouth ulceration and peripheral 
neuropathy.
Throughout the late 1990’s and early 2000’s the choice 
of nucleoside backbone became a matter of fashion with 
stavudine and lamivudine being the most frequently pre-
scribed due to relatively good tolerability and the belief 
that stavudine had a better barrier to drug resistance than 
AZT. A combination of stavudine and didanosine was also 
frequently used although the emergence of cases of lactic aci-
dosis and hepatic steatosis associated with this combination 
moved it out of vogue (Carr 2000). The arrival of Combivir 
in 1997 lead to a new dawn for AZT and many clinical trails 
have supported this NRTI backbone in terms of efﬁ  cacy and 
a relatively good tolerability and toxicity proﬁ  le. The ACTG 
384 study demonstrated the advantages of this combination 
over the prescription of stavudine and didanosine (Robbins 
2003). Stavudine has been associated with the development 
of peripheral and facial lipoatrophy (Dube 2002) and this has 
almost eliminated its use in current practice.
Combivir became the gold standard and most frequently 
prescribed nucleoside backbone in initial HIV therapy. This 
has subsequently been supported by the results of several 
large randomized studies (Robbins 2003; Gulick 2004). 
However more recently, AZT has been associated with 
development of lipoatrophy in some of those using the drug in 
the long-term (Martin 2004). AZT also has the disadvantage 
over newer NRTI backbones of requiring twice daily dosing. 
Tenofovir (TDF) containing and abacavir (ABC) contain-
ing regimens may have better short term tolerability and 
compared to tenofovir containing regimens, AZT containing 
regimens have been shown to lead to more discontinuations 
due to anemia (Pozniak 2006).
Contemporary HIV treatment guidelines reflect the 
uncertainty as to which NRTI backbone is most suitable for 
therapy naïve individuals. Combivir has the most experience 
and clinical trial data behind it, yet concerns about short term 
tolerability and toxicity and the emergence of lipoatrophy has 
limited its use. The competing ﬁ  xed dose NRTI/Nucleotide 
backbones of Truvada® (tenofovir disoproxil fumarate and 
emtricitabine(FTC)-Gilead sciences) and Kivexa®/Epzicom® 
(abacavir and lamivudine-GlaxoSmithKline) have some 
supporting data but are not without disadvantages them-
selves. Concerns have been raised about renal toxicity from 
tenofovir (Gallant et al 2005) and 5% of individuals on abacavir 
develop a potentially life threatening hypersensitivity reac-
tion (Hernandez 2003).
Vertical transmission of HIV from an HIV infected 
mother to child is a major cause of infection particularly in 
the developing world where there is limited access to anti-
retroviral medication. Multiple factors inﬂ  uence the risk of 
mother to child transmission (MTCT) including amongst 
others stage of disease, CD4 count, maternal viral load and 
method of delivery. The risk for MTCT whilst pregnant has 
been calculated in studies to be 12–25% in the developed 
world if a mother does not take antiretroviral therapy, reduc-
ing to as low as 2% if antiretrovirals are commenced and 
HIV viral load becomes undetectable (Cooper 2002). The 
risks are higher in resource limited settings. Antiretroviral 
therapy consisting of maternal oral AZT monotherapy dur-
ing pregnancy, intravenous AZT during labor and oral AZT 
given to the baby was shown to reduce the risk of MTCT by 
two thirds in the ACTG 076 trial (Connor 1994). AZT was 
the ﬁ  rst and is the most studied of all licensed antiretrovirals. 
Both AZT and 3TC are classiﬁ  ed as Category C drugs in 
pregnancy by the FDA and there has yet been no evidence of 
teratogenicity with their usage (Covington 2004). This clas-
siﬁ  cation means that these drugs can be used in pregnancy 
if the potential beneﬁ  ts outweigh the risks. AZT and 3TC 
are the preferred NRTIs during pregnancy (Mofenson et al 
2002). As there is more data to support the use of AZT/3TC 
in pregnancy, Combivir therefore has a lead over other ﬁ  xed 
dose combinations in particular scenarios during pregnancy 
though there have been no formal studies of the use of Com-
bivir in pregnancy to date.
Antiretroviral drugs are used as post exposure prophy-
laxis (PEP) agents against HIV infection for both occupa-
tional and sexual exposure. Their use is widespread in many 
countries and in different situations. Although not a licensed 
indication for its use, retrospective case controlled studies 
in healthcare workers have shown that AZT monotherapy 
in occupational exposure was protective against infection 
(Cardo 1997). AZT is the only antiretroviral currently to 
have been studied which has shown evidence of the reduc-
tion in transmission of HIV. For this reason many clinicians 
choose to incorporate this drug as part of a combination in 
PEP. As previously mentioned, triple combination therapy 
is more effective than one or two drugs for virological 
suppression so it is biologically plausible that three drugs 
are preferential than one or two drugs in PEP for prevent-
ing HIV transmission following exposure. Zidovudine is 
favored over the use of abacavir in PEP due to the risks of 
abacavir hypersensitivity (Hernandez 2003). The low pill 
burden and simple dosing schedule facilitates is usefulness 
for this purpose.Therapeutics and Clinical Risk Management 2007:3(4) 582
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So what is the future of Combivir? GlaxoSmithKline’s 
patent on AZT expired in September 2005 and so the pos-
sibility of cheaper, generic versions of AZT may affect 
Combivir sales. 3TC may be dosed once daily but due to the 
short intra-cellular half life of AZT means it must be dosed 
twice daily. The simplicity of once daily therapy, which may 
have advantages for treatment adherence (Portsmouth 2004) 
and the improved tolerability of the ﬁ  xed dose combinations 
of Kivexa and Truvada has lead to these becoming the most 
frequently used backbones. Despite Combivir having no 
food restrictions many patients ﬁ  nd taking AZT on an empty 
stomach difﬁ  cult and experience nausea.
Studies comparing ABC + 3TC or TDF + FTC to Com-
bivir have not shown superiority to Combivir as a nucleoside 
backbone. The CNA30024 (DeJesus 2004) study indicated 
that in treatment naïve individuals starting ABC + 3TC + 
efavirenz was as effective over 48 weeks as AZT + 3TC + 
efavirenz. This was not a head to head trial using the ﬁ  xed 
dose combinations of Kivexa or Combivir as the components 
were given individually. The GS934 Study (Pozniak 2006) 
shows non-inferiority using Truvada + efavirenz compared 
to Combivir + efavirenz at 96 weeks.
Patients experiencing treatment failure on Combivir 
develop resistance patterns which differ from those acquired 
by individuals using other ﬁ  xed dose combinations. Patients 
experiencing treatment failure on Combivir as a ﬁ  rst line com-
bination commonly acquire the M184V mutation, reducing 
susceptibility to lamivudine. This helps increase the sensitivity 
to AZT and can protect against acquiring further thymidine 
analogue associated mutations. Combivir may have some uses 
in second line and in selected treatment experienced patients 
as guided by genotypic resistance assays. Virological failure 
on a tenofovir based regime and sometimes on abacavir based 
regimens leads to the development of the K65R mutation in 
reverse transcriptase (Winston 2002). Abacavir failure may 
lead to the development of the L74V mutation and both of 
these mutations result in a virus that retains sensitivity to AZT 
(Miranda 2005). Thus if an individual has initiated therapy 
with either Kivexa or Truvada and then experiences virologi-
cal failure it is likely that the resistance proﬁ  le of their virus 
will retain susceptibility to AZT (Parikh 2006). It would also 
be very likely that they would also have developed virus with 
the M184V mutation. Treating physicians may wish to retain 
the presence of lamivudine in a patient’s regimen especially 
if the individual has hepatitis B co-infection. 3TC has activity 
against this virus and stopping 3TC may lead to a hepatitis 
ﬂ  are associated with resurgence in hepatitis B virus load. HIV 
harboring the M184V mutation often has a reduced replica-
tive capacity and may lead to slower disease progression in 
some circumstances (Castagna 2006). In later lines of therapy 
some physicians may wish to leave 3TC in a regimen to drive 
this mutation production and so keep this mutation present. 
Zidovudine does have well established efﬁ  cacy at penetrat-
ing the blood brain barrier and so conﬁ  dence remains in its 
ability to prevent and treat HIV related neurological disease 
(Enting 1998).
Conclusion
In summary, Combivir was the ﬁ  rst ﬁ  xed dose combination 
antiretroviral agent and for some time has maintained a place 
as the gold standard in HIV therapy for treatment naïve indi-
viduals. It is a highly potent combination but recent concerns 
over the potential to cause lipoatrophy, and the introduction 
of better tolerated once daily ﬁ  xed dose combinations means 
that Combivir has lost favor as the nucleoside containing 
backbone of choice.
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